What's Happening?
Alumis has announced positive results from its phase 3 trials for envudeucitinib, an oral TYK2 inhibitor for treating psoriasis. The trials, ONWARD1 and ONWARD2, demonstrated significant skin clearance,
with 65% of patients achieving a 90% or better response at 24 weeks. Envudeucitinib could become a competitor to Bristol Myers Squibb's Sotyktu, which has been on the market since 2022. Alumis' drug showed superior efficacy compared to existing oral therapies, and its shares surged by 82% following the announcement.
Why It's Important?
The success of envudeucitinib in clinical trials positions Alumis as a strong contender in the psoriasis treatment market, potentially challenging established drugs like Sotyktu. This development could lead to increased competition and innovation in the field of dermatology, offering patients more effective treatment options. The promising results also highlight the potential of TYK2 inhibitors in managing autoimmune conditions, which could have broader implications for other diseases.
What's Next?
Alumis plans to file for regulatory approval of envudeucitinib later this year. The company is also exploring the drug's potential in treating systemic lupus erythematosus, with phase 2b results expected in 2026. As the market for psoriasis treatments evolves, stakeholders will be closely monitoring regulatory decisions and market responses to new therapies.
